The primary study hypothesis was that ranibizumab @ mg monotherapy or combined with laser is superior to laser monotherapy based on mean average change in best-corrected visual acuity ( BCVA ) over @ months in Asian patients with visual impairment resulting from diabetic macular edema ( DME ) .